QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

DNLI

QT58Denali Therapeutics Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
23.31
-0.18-0.77%
OverviewShort InterestFilings
DNLIQT58Denali Therapeutics Inc.·NASDAQ
OverviewShort InterestFilings
23.31-0.77%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-0.96
Insider Own27.39%
Shs Outstand158.71M
Perf Week10.89%
Market Cap3.73BForward P/E-EPS next Y-2.42Insider Trans-0.03%Shs Float-Perf Month28.71%
Enterprise Value3.38BPEG1.11EPS next Q-0.58Inst Own-Short Float-Perf Quarter18.03%
Income-432085831.00P/S0.00EPS this Y-152.74%Inst Trans-Short Ratio-Perf Half Y36.96%
Sales-P/B4.73EPS next Y0.28%ROA-40.13%Short Interest-Perf YTD41.19%
Book/sh5.83P/C-EPS next 5Y-ROE-52.20%52W High24.65 -5.44%Perf Year66.38%
Cash/sh6.23P/FCF-EPS past 3/5Y-ROIC-46.93%52W Low12.58 85.29%Perf 3Y-
Dividend Est.-EV/EBITDA-6.85Sales past 3/5Y-Gross Margin0.00%Volatility3.96% 3.79%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-12.06%Oper. Margin0.00%ATR (14)1.17Perf 10Y-
Dividend Ex-Date-Quick Ratio9.28Sales Y/Y TTM-Profit Margin0.00%RSI (14)67.72Recom2.00
Dividend Gr. 3/5Y-Current Ratio9.28EPS Q/Q11.54%SMA2012.83%Beta1.72Target Price30.80
Payout0.00%Debt/Eq0.04Sales Q/Q-SMA5016.58%Rel Volume1.43Prev Close23.49
Employees443LT Debt/Eq0.03EarningsAug 10SMA20026.89%Avg Volume1.76MPrice23.31
IPO DateDec 08, 2017Option/ShortYes / YesEPS/Sales Surpr.5.48% -Net Debt/EBITDA0.70Volume2,517,683Change-0.77%
Analyst Ratings
DateActionAnalystRatingTarget
May-22-26ReiteratedDeutsche Bank$35 → $31
May-08-26ReiteratedWedbushOutperform$30 → $23
Mar-26-26ReiteratedDeutsche Bank$26 → $35
Mar-02-26ReiteratedJefferiesBuy$45 → $40
Jan-08-26ReiteratedMorgan StanleyOverweight$32 → $40
Jan-07-26ReiteratedUBSBuy$70 → $25
Dec-11-25ReiteratedWedbushOutperform$31 → $30
Dec-05-25ReiteratedWedbushOutperform$31
Nov-17-25ReiteratedStifel Nicolaus$22 → $37
Jan-07-25ReiteratedBTIGNeutral$35 → $32
Latest News
Jun-18-26
Jun-18-2608:07AM
Denali Therapeutics Signs Deal To Sell Its Rare Pediatric Disease Priority Review Voucher For $195MBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue34000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A0110
Gross Profit340-110
Selling, General and Administrative Excl. Other10297105
Research and Development409419396
Other Operating Expense028-14
Operating Income-170-555-487
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-45-4315
Net Income Before Taxes-125-512-423
Income Taxes000
Consolidated Net Income-125-513-423
Net Income From Continuing Operations-125-513-423
Net Income-125-513-423
EPS (Recurring)-0.92-2.97-2.57
EPS (Basic, Before Extraordinaries)-0.92-2.97-2.57
EPS (Diluted)-0.96-2.97-2.57
EBITDA-106-498-493
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
9.46——
Gross Margin100.00——
Operating Margin-50.00——
Net Margin-36.76——
Shares Outstanding138175164
Market Capitalization3,2172,889—
Operating Lease Expense
———
Insider Trading Volume
$25.31$22.26$19.21$16.16$13.11● Close Price0.00M1.86M3.71M5.57M7.43MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Schuth Alexander O.COFO and SecretaryJan 06 '26Sale16.5017,218284,097282,828Jan 08 12:00 AM
Watts Ryan J.President and CEOJan 06 '26Sale16.5035,198580,767296,833Jan 08 12:00 AM
BAKER BROS. ADVISORS LPDirectorDec 11 '25Buy0.012,285,71422,85725,996,310Dec 15 12:00 AM
Ho CaroleChief Medical OfficerAug 13 '25Sale14.6480611,800216,585Aug 14 12:00 AM
Schuth Alexander O.COFO and SecretaryAug 12 '25Sale13.582,93739,884242,346Aug 14 12:00 AM
Ho CaroleChief Medical OfficerAug 12 '25Sale13.582,93739,884217,391Aug 14 12:00 AM
Ho CaroleChief Medical OfficerAug 05 '25Option Exercise0.6889,31060,730220,328Aug 07 12:00 AM
Watts Ryan J.President and CEOJul 09 '25Option Exercise1.05990,5641,041,584748,353Jul 11 12:00 AM
Watts Ryan J.President and CEOJul 09 '25Sale15.00495,2827,429,230253,071Jul 11 12:00 AM
Ho CaroleChief Medical OfficerJan 07 '25Sale20.812,90760,495175,673Jan 08 12:00 AM
Krognes Steve E.DirectorJan 07 '25Sale20.813,33969,48525,757Jan 08 12:00 AM
Watts Ryan J.President and CEOJan 07 '25Sale20.817,650159,197253,071Jan 08 12:00 AM
Schuth Alexander O.COFO and SecretaryJan 07 '25Sale20.812,90760,495244,308Jan 08 12:00 AM
Schuth Alexander O.COFO and SecretaryJan 06 '25Sale20.2212,255247,796247,215Jan 08 12:00 AM
Ho CaroleChief Medical OfficerJan 06 '25Sale20.2212,255247,796178,580Jan 08 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR